- $932.79m
- $789.86m
Brief: Savara Initiates Rolling Submission Of A Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis (Apap)
Brief: Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) At The British Thoracic Society Winter Meeting 2024
Savara Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Savara Q3 Net Income USD -24.248 Million
Brief: Savara Announces Expanded Access Program For Molgramostim Inhalation Solution For Patients With Autoimmune Pulmonary Alveolar Proteinosis
Brief: Savara Appoints Braden Parker As Chief Commercial Officer, Effective Immediately
Savara Inc reports results for the quarter ended in June - Earnings Summary
Brief: Savara Q2 Net Income USD -22.243 Million
Savara Inc expected to post a loss of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Altimmune, General Mills, Whirlpool
U.S. STOCKS ON THE MOVE-Grindr, FedEx, Moderna
U.S. STOCKS ON THE MOVE-Apple, SolarEdge Technologies, Taysha Gene Therapies
U.S. STOCKS ON THE MOVE-Nvidia, FedEx, Rivian
Savara jumps on success of lung disease therapy in late-stage trial
Savara's rare lung disease drug meets main goal in late-stage study (updated)
Savara's rare lung disease drug meets main goal in late-stage study
Brief: Savara Announces Molgramostim Nebulizer Solution Achieved Statistical Significance For Primary Endpoint
U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International
Savara Inc reports results for the quarter ended in March - Earnings Summary